High-calorie diet-induced obesity leads to cardiomyocyte dysfunction and apoptosis. Impaired regulation of epididymal fat content in obese patients has been known to increase the risk of cardiac injury. In our study, a lactic acid bacteria, Lactobacillus reuteri GMNL-263, was evaluated for its potential to reduce body weight and body fat ratio and to prevent heart injury in rats with high-fat diet-induced obesity. Lactic acid bacteria supplementation restored the cardiac function and decreased the physiological changes in the heart of the obese rats. In addition, the Fas/Fas-associated protein pathway-induced caspase 3/e Poly polymerase mediated apoptosis in the cardiomyocytes of the obese rats was reversed in the Lr263-treated rats. These results reveal that fed with Lr-263 reduces body fat ratio, inhibits caspase 3-mediated apoptosis and restores cardiac function in obese rats through recovery of ejection fraction and fractional shortening. Our results indicated that the administration of Lr263 lactic acid bacteria can significantly down-regulate body fat and prevent cardiomyocyte injury in obese rats.
Introduction
Obesity is a metabolic disease characterized by an excess accumulation of fat and the presence of some genetic defects such as TMEM18, SH2B1 and GNPDA2 had been shown that associated with obesity in clinical research [1] . Moreover, obesity also induces other complication disease, i.e., hyperlipidemia, inflammation, oxidative stress, myocardial apoptosis, lipid metabolic disorders and insulin resistance, and these pathological factors are associated with increased risks for the development of cardiovascular diseases (CVD) [2] [3] [4] [5] [6] .
High-calorie intake often leads to obesity, insulin resistance, apoptosis, oxidative stress, hypertension and induced endoplasmic reticulum (ER) stress,
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International Publisher which lead to the development of CVD [7] [8] [9] . The molecular mechanism behind obesity-driven tissue injury in mice and rats fed high-calorie diets involves caspase and poly (ADP-ribose) polymerase (PARP) activation, inducing apoptosis and leading to cardiac dysfunction [10] . Other mechanisms, including the up-regulated apoptotic response and mitochondrial dysfunction, decrease the survival rate of cardiomyocytes in genetically obese mice [11] . Additionally, some studies have suggested that apoptosis plays an important role in the pathogenesis of CVD [12] [13] [14] .
In cardiomyocytes, first apoptosis signal (Fas)-and mitochondria-dependent apoptotic pathways are the major pathways leading to myocyte apoptosis [15, 16] . In our previous study observed that cardiac apoptosis through Fas-dependent pathway activation in Zucker rats, a genetic animal model for obesity. Fas ligand levels induce caspase-8 activation and promote cardiomyocyte apoptosis, indicating the Fas receptor-dependent apoptosis pathway in obesity-associated heart disease [17] . Other reports also note that the up-regulation of the cardiac mitochondria-dependent apoptosis pathway via BCL2-Associated Agonist Of Cell Death (Bad) dephosphorylation and cytochrome c release is accompanied by a decreased expression of B-cell lymphoma 2 (Bcl-2), which is an anti-apoptotic factor present in obese rats [18] . Moreover, both the Fas-dependent pathway and the mitochondria-dependent pathway trigger caspase-3 activation and cause PARP cleavage [19] .
A previous study indicated that the insulin-like growth hormone (IGF-1) signaling pathway regulated cardiomyocyte survival responses through by IGF-1 receptor (IGF-1R), and low IGF-1 levels are highly correlated with heart failure and myocardial infarction [20] . IGF-1 activates phosphatidylinositol-3 kinase/Akt (PI3K/AKT) pathway, which leads to the prevention of myocyte apoptosis [21] . More importantly, activated PI3K promotes Akt phosphorylation, which increases Bcl-2 expression to down-regulate cardiomyocyte apoptotic activity [21] . In obese rats, reduced body fat accumulation, inflammation, oxidative stress and increased PI3K/Akt activation prevent cardiomyocyte remodeling and cardiac dysfunction [22] .
Effects of probiotic on many metabolic-related diseases and immune-regulation have been reported extensively in several in vitro, in vivo research and clinical trials [23] [24] [25] [26] [27] [28] [29] . Previous studies indicated that supplemental probiotic decreased low-density lipoprotein (LDL), total cholesterol levels and reduced body weight and fatty liver [30] . In our previous study, we found that oral lactic acid bacteria reduced blood glucose and prevented heart injury in rats with streptozotocin-induced diabetes mellitus (DM) [31] . Moreover, lactic acid bacteria supplementation inhibited the pro-inflammatory and inflammatory cytokines secreted in type 1 DM animal model [32] and down-regulated insulin levels in a type 2 DM animal model [33, 34] . However, the application of probiotic for the prevention of cardiomyocyte apoptosis induced by high calorie-induced obesity and CVD have not been extensively explored [33] .
Previous studies indicated that Lactobacillus reuteri GMNL-263 (Lr263) had some biologic effect such as down-regulated blood lipids in a hyperlipidemia hamster model [35] , prevented liver injury and improved insulin resistance in high fructose-fed rats [36] and provided renal protection in diabetic rats [37] . Although these reports showed the biological effect of Lr263, there is no enough evidence to indicate Lr263 exhibits cardio protection. In this study, we established high-calorie diet animal model to determine the effect of oral heat-killed Lr263 in heart protection.
Materials and methods

Preparation of bacterial suspensions
Lactobacillus reuteri GMNL-263 (Lr263), deposited under the Bioresource Collection and Research Center (BCRC) accession no. BCRC 910452, was provided by the GenMont Biotech, Inc. Lr263 was statically grown in Man Rogosa Sharpe (MRS; BD Difco, Franklin Lakes, NJ) broth at 37°C for 18-20 h. The bacterial culture was harvested using centrifugation (4000 ×g, 15 min), washed twice with PBS, autoclaved, and resuspended to a final concentration of either 4.13x10 8 or 2.07x10 9 cells /kg/day for daily oral administration to rats during the 4-8 weeks experiment.
Animal model
The animal experiment protocol (NO. 101-263-B) was approved by Institutional Animal Care and Use Committee of China Medical University. Sprague-Dawley rats which were from BioLASCO Taiwan Company Limited and set up for four groups randomly (n = 5 each). The control group rats administered with normal saline (N), group II was high-calorie diet-fed rats (HC), and groups III and IV were high-calorie diet rats supplemented with the low-dose of Lr263 (4.13x10 8 cells /kg/day, HCL) and the high-dose of Lr263 (2.07x10 9 cells /kg/day, HCH). The dose of Lr263 was selected based on the recommended dietary allowance (RDA) for human (low-dose, 1 fold: 4x10 9 cells/day and high-dose, 5 folds: 2x10 10 cells /day) and calculated using the following equation: 4x10 9 / 60 kg (human weight) X 6.2(rats conversion) = 4.13x10 8 , 5 folds: 2.07x10 9 for rats. The animals were housed individually; the temperature was maintained at 20±2˚C 1with 55±5% humidity. The rats were maintained on a 12-h dark-light cycle with lights on from 9 AM to 9 PM. The normal diet (AIN-76, protein 18.6%, fat 10% and carbohydrates 60.6%) was purchased from Young Li Company (Taipei, Taiwan); the high-calorie diet was the normal diet with added soybean oil (8%) and condensed milk (44%) to simulate the lifestyle diet. All rats had access to water ad libitum during the experimental period. Following the 8-week experimental period, all the rats were sacrificed.
Echocardiography
Rats were anesthetized by 3% isoflurane and 97% oxygen, fixed and supine on a acrylic board, shaved the chest hair. We measured the echocardiography by echocardiographic machine (ultrasound system -Vivid 7, GE Healthcare, Milwaukee, Wis). The heart imaged by the 2-dimensional mode near parasternal long-axis and short-axis view of the left ventricle obtained.Used these views were to measure the direct location of the M-mode cursor. M-mode echocardiographic examinations were conducted using a 6-15 MHz linear transducer (15-6 L) via a parasternal long-axis approach. LV M-mode measurements at the level of the papillary muscles included LV internal end-diastolic dimensions, LV internal end-systolic dimensions, interventricular septum and posterior wall thicknesses, ejection fraction (EF) and fractional shortening (FS).
Physiological features measuring
Rats were weighed every week during the experiment. The total body fat was measured from the surface of epididymal. The body fat ratio (%) calculated using the following equation:
Body fat ratio = (total body fat (g)/body weight (g)) X 100
The food intake was weighed every day during the experiment. The food utilization rate (%) was calculated using the following equation:
Food utilization rate = (total body weight gain (g)/total food intake (g)) X 100
Hematoxylin and eosin staining
The rat hearts tissue for each groups were incubated with formalin, next dehydrated in graded alcohol (100, 95 and 75%) and embedded in paraffin wax. Cut tissue sample blocks into 0.2 μm-thick sections. Before staining incubated the tissue sections with xylene to deparaffinised. After deparaffinised the tissue sections were stained by hematoxylin and eosin and washed with water. The data collected using a Zeiss Axiophot microscope (OLYMPUS Microscopy).
Tissue protein extraction
The cardiac tissue extracts (left ventricular) of the rats in a lysis buffer (1 mg/ml). The sample buffers were placed on ice for 30 min and next centrifuged at 13500 g for 20 min. The supernatants were collected and stored at -80°C for use in further experiments. The composition of lysis buffer is 20mM Tris, 2mM EDTA, 50mM 2-mercaptoethanol, 10% glycerol, protease inhibitor per/10ml and phosphatase inhibitor 1μl/ml.
Western blot analysis
The protein sample buffer of the cardiac tissue extracts were determined by Lowry's protein assay method and load 15μg per sample in each well. To analysis protein samples by SDS-PAGE (12%, 10% and 8%) and supply of 100 V. Next we transferred the protein onto the polyvinylidene difluoride (EMD Millipore Life Sciences) membranes by 90 V, 70 min. The membranes were blocking by 5% fat-free milk in Tris-buffered saline (TBS) for 1 hour, after washed by TBS buffer the membranes incubated with primary antibodies to specific proteins : p-Akt (sc-5298, Santa Cruz Biotechnology), Bcl-2 (sc-7382, Santa Cruz Biotechnology), cleaved caspase 3 ( #9664, Cell signaling), GAPDH (sc-25778, Santa Cruz Biotechnology) and dilution 1000x. After incubated with secondary antibodies the membranes were used for detection by with Fujifilm LAS-4000 (GE Healthcare Life Science).
TUNEL assay
The terminal deoxynucleotidyltransferase 2'-deoxyuridine 5'-triphosphate (dUTP)-mediated nick-end labeling (TUNEL) assay, tissue sections were dehydrated using graded alcohol (70%, 90%, 100%, 10 min for each), rinsed three times in xylene, and incubated with proteinase K for 30 min; washed with PBS, incubated with a permeabilization solution (5% Triton buffer) and incubated in a blocking buffer for 1 hr; and finally washed twice with PBS. The sections were then incubated for 60 min at 37°C with the TUNEL assay buffer (Roche Applied Science). The TUNEL-positive nuclei were showed by green color detected by florescence microscope (OLYMPUS).
Statistical analysis
The results are reported as the means and standard deviations of three independent analysis experiments, for western blot analysis, the experiments were repeated three times with corresponding blots from 4 different tissue slices. Statistical analysis was performed using one-way ANOVA. *P<0.05, **P<0.01 or ***P<0.001: the mean values were significantly different from those of the N group, #P<0.05, ##P<0.01 or ###P<0.001: the mean values were significantly different from those of the HC group.
Results
Physiological features
As shown in Table 1 , the average body weight in the HC group was 573.4 g (sd 39.4), (19.4% higher than in the N group); the food intake was 1226.6 g (sd 100.8), (15% lower than in the N group); the food utilization rate was 14.6% (sd 3.2), (1.8-fold higher than that N group); and the epididymal fat content was 2.1% (sd 0.4), (1.75-fold higher than in the N group). The body weight of rats treated with low-dose Lr263 was 493.8 g (sd 32.1), (13.8% lower than in the HC group); the food intake was 1189.8 g (sd 50.6), (2% lower than in the HC group); the food utilization rate was 12.1% (sd 4.4), (0.8-fold lower than in the HC group); and the epididymal fat content was 1.8% (sd 0.4), (0.8-fold lower than in the HC group). Moreover, The body weight of the rats treated with high-dose Lr263 was 470.8 g (sd 27.9), (17.9% lower than that HC group); the food intake was 1164.8 g (sd 29.5), (5% lower than in the HC group); the food utilization rate was 12.6% (sd 4.4), (0.86-fold lower than in the HC group); and the epididymal fat content was 1.4% (sd 0.4), (0.66-fold lower than in the HC group). These results indicated that Lr263 functional food treatment may prevent the detrimental effects of a high-calorie diet on the physiological features rats.
Cardiac echocardiography
Previous studies obtained that ejection fraction (EF (Teich)) and fractional shortening (FS) decreased in different heart disease models especially in heart failure [38] [39] [40] [41] , therefore, EF (Teich) and (FS) were considered as heart function markers.
After one month of Lr263 supplementation, the heart function markers: EF (Teich) and FS was determined by cardiac echocardiography. The average EF (Teich) in the control group rats was 80.0% (SD 2.5), and the average FS was 43.9% (SD 2.4) ( Table  2 ). The average EF (Teich) of the high-calorie group was 71.9% (SD 5.4), (8% lower than that of the N group rats), and the average FS was 38.7% (SD 4.6), (5.2% lower than that of the N group rats). The average EF (Teich) of the HCL group rats was 77.2% (SD 5), (5.2% higher than that of the HC rats), and the average FS was 41.4% (SD 4.7), (2.7% higher than that of the HC rats). The average EF (Teich) of the HCH rats was 80% (SD 2.5), (8.1% higher than that of the HC rats), and the average FS was 43.8% (SD 2.6), (5.1% higher than that of the HC rats). 
Cardiac tissue biopsy
The cardiac tissue sections of the high-calorie-induced obese rats stained with hematoxylin and eosin showed that the arrangement of the cardiomyocytes was disordered compared with the N group. After treatment with Lr263, the arrangement of the cardiomyocytes was more ordered than in the HC rats; the arrangement of the cardiomyocytes of the HCH rats was similar to that of the N group rats (Fig. 1) .
Protein marker analysis
The important apoptosis and survival protein marker expression levels of the hearts were determined by Western blot analysis of the cardiac tissue extracts. In our results, the expression levels of the apoptosis marker caspase 3 and the downstream protein PARP in the hearts of the HC group rats were much higher than in the N group rats (Fig. 2A) . The expression levels of the survival protein marker p-Akt and the downstream protein Bcl-2 were also down-regulated in the hearts of the HC group rats (Fig. 2A) . The expression levels of caspase 3 and PARP of the HCL and HCH groups were lower than the hearts of the HC group rats. The expression levels of p-Akt and Bcl-2 in the hearts of the HCL and HCH groups were increased compared with the HC group and were even higher than the hearts of the N group rats. Moreover, analysis of the protein expression ratios indicated that, in the rat hearts, treatment with Lr263 prevented heart injury by the up-regulation of Bcl-2 and the down-regulation of caspase 3 and PARP proteins in a dose-dependent manner (Fig 2. C-E) .
Cardiac apoptosis assay
The TUNEL-positive nuclei showed a higher number (6-fold higher than in the N group) of apoptosis in the heart tissue sections of the HC group rats (Fig 3. B) . After treatment with low-dose and high-dose Lr263 showed that Lr263 down-regulated cardiomyocyte apoptosis. Moreover, Lr263 reduced the cardiomyocyte apoptosis in the HCL and HCH groups, with 3-fold and 4-fold lower apoptotic rates than in the HC group, respectively. Our results indicate that Lr263 prevents cardiomyocyte apoptosis induced by a high-calorie diet in a dose-dependent manner.
Discussion
Several studies showed lactic acid bacteria biological functions involved anti-inflammatory, antioxidant, anti-cancer, blood pressure and plasma lipid regulation activities [42] [43] [44] . Furthermore, lactic acid bacteria are known to down-regulate blood glucose levels and prevent complications of diabetes [45] . Other studies have shown that lactobacilli provide cardioprotection against ischemia and diabetes-induced apoptosis [46, 47] . The high-calorie and high-fat diet-induced obesity animal model exhibits features of the pathophysiological disease as it occurs in human obesity, including diabetes, cardiac hypertrophy and cardiovascular dysfunction [48, 49] . Probiotics change the intestinal microflora profile and thereby brings change in the general metabolism. It is worthy to mention that we cannot predict the lactic acid bacteria growth number in rats intestinal, further other reports indicated both the live as well as dead lactic acid bacteria have potential beneficial effects [50, 51] . So in this study we used the heat shock lactic acid bacteria to investigate the dose-specific effects of Lr263 in high calorie-fed rat hearts. Moreover, recent research has clearly indicated that feeding mice a high-fat diet was associated with a body mass increase and significant modifications in blood lipids and glucose homeostasis, fat accumulation and adipocyte remodeling [52] . However, the use of functional foods in the management of lifestyle diseases, particularly in obesity and CVD, has not been investigated extensively. In a healthy rat, the numerical value of EF is near 80, and the FS value is higher than 40; however, in a healthy human, the numerical value of EF is near 55, and the FS value is higher than 30. EF or FS values below the normal range may indicate the development of cardiac dysfunction [53] . In this study, decreases in the values of EF (by 8.1%) and in those of FS (by 5.1%) reveal the onset of cardiac dysfunction. The cardiac dysfunction was also accompanied by deterioration in cardiomyocyte characteristics such as the cardiomyocyte derangement in rats with high-calorie-induced obesity. However, treatment with a high dose of Lr263 (2 x10 10 cell counts) maintained the percentage of epididymal fat at 1.4% and controlled the body weight at 470.2 g in the rats with high-calorie-induced obesity. Moreover, the EF and FS values were above 80% and 43%, similar to the control group (Table 2) . Furthermore, the hematoxylin and eosin staining analysis of the biopsies showed that treatment with Lr263 decreased cardiac injury, and the hearts of the rats in the high-dose group were similar to the control group. Therefore, supplementation with Lr263 is found was found to provide cardioprotection in obese rats.
In control group epididymal fat content in healthy rats is approximately 1% of the body weight, the average epididymal fat content in the rats with high-calorie induced obesity was observed to be above 2.1%, and Lr263 treatment reduced the epididymal fat content to 1.8% in the low-dose group and 1.4% in the high-dose group. Although epididymal fat content was not down-regulated to normal levels after Lr263 treatment in all rats, the adverse symptoms of the obesity group were reduced. Thus, high-calorie induced obesity may only increase risk when the epididymal fat content rises above 2.1%, and therefore, control of the epididymal fat content is a key target to evaluate fat accumulation in obese patients.
Obesity is a strong risk factor for the development of cardiac dysfunction, particularly hypertrophy. Obesity has been shown to up-regulate BNP protein, a key factor in the development of hypertrophy, which may result in heart failure [54] . The characteristics of heart failure involve progressive left ventricular dysfunction and loss of cardiomyocytes via necrosis or apoptosis [55] . Previous studies have shown that obesity increases the incidence of heart disease by 50% compared with humans at their target weight [56] . In our recent studies, the major pathways leading to the activation of the cleavage of caspase 3 and PARP, resulting in cardiac dysfunction [47, 57, 58] .
Caspase 3 and PARP cleavage and activation were significantly suppressed in a dose-dependent manner by low-dose (4.13x10 8 cells /kg/day) and high-dose (2.07x10 9 cells /kg/day) Lr263 treatments ( Fig. 2) . Moreover, the expression levels of p-Akt and Bcl-2 were also significantly up-regulated by Lr263 treatment (Fig. 2) , although biopsy analysis of the heart damage in rats with high-calorie induced obesity showed a dose-dependent reversal after Lr263 treatment (Fig. 1) . In addition, the TUNEL assay showed that Lr263 supplementation reduced the percentage of apoptosis in rat hearts induced by a high-calorie diet. These results indicated that Lr263 treatment decreased the body fat ratio and down-regulated the expression of caspase 3 and PARP, preventing cardiac dysfunction in obese rats. The mechanism of Lr263-mediated cardioprotection and body fat control in obese rats requires further investigation.
Our experimental results clearly indicate that high-calorie diets successfully induce obesity in rat models, leading to cardiac dysfunction and body fat accumulation. Importantly, supplementation with Lr263 reduced body fat accumulation and body weight. Moreover, our data show that treatment with Lr263 prevented cardiac injury in obesity animal models. This finding indicates that Lr263 could be used as a complementary therapy in the prevention and treatment of cardiac disorders and the possible mechanisms may via decreased apoptosis protein (cleaved caspase 3 and PARP) expression and up-regulated survival protein (p-Akt and Bcl-2) expression and cardiac function (EF% and %FS) .
